Depressive Disorders

Depression is a common and costly disorder affecting more than 120 million people worldwide. There is a need for new drugs to improve the treatment of depressive disorders. Prous Institute is targeting depression with two series of compounds, including the following:

Target / Action Status
JRP 227
Monoamine uptake / Inhibitor        
JRP 362
Monoamine uptake / Inhibitor Preclinical

Neurodegenerative Diseases

Autophagy is a major catabolic process that has been implicated in a number of human diseases and is a potential target for therapeutic intervention. Prous Institute is developing a research program focused on the discovery of new small molecule modulators of autophagy as therapeutic agents for Alzheimer’s disease, Parkinson’s disease and Huntington’s disease. Another program is focused on agents influencing neuroplasticity functions.

Compounds are tested using a behavioral phenotypic screen in mouse models reproducing signs and symptoms displayed by human patients, and in in vitro and in vivo mechanistic models of the disease.

Alzheimer’s Disease

It has been estimated that about 30 million people worldwide have dementia, the majority of whom have Alzheimer’s disease (AD). This neurodegenerative disease represents a major public health concern and has been identified as a research priority. There is an urgent need to find new disease-modifying treatments, since at present only a few treatments exist to alleviate the symptoms of AD.

Amyotrophic Lateral Sclerosis (ALS)

ALS is an idiopathic fatal neurodegenerative disease of the human motor system. According to the International Alliance of ALS, ALS affects more than 350,000 people worldwide. The incidence of ALS is five times that of Huntington’s disease. Disease management strategies are needed to control the symptoms of ALS – including dysphagia, dysarthria, respiratory distress, pain and psychological disorders.

Huntington's Disease

Huntington's disease (HD) is another neurodegenerative disorder that has no cure, and management is based on treating symptoms with a view to improving quality of life.

Parkinson's Disease

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease after Alzheimer’s disease (AD). The number of individuals with PD in Western Europe was approximately 4.5 million in 2005, and it is expected to double by 2030. As in the case of AD, there is a need to find new disease-modifying treatments; i.e., drugs capable of slowing or reversing the disease’s progression.

Compounds being developed in the neurodegenerative disease area include:

Target / Action
JRP 655 Neuroplasticity / Modulator            
JRP 900
Autophagy / Inductor     Preclinical